Free shipping on all orders $250CAD or more within Canada.

Adipotide

Adipotide

SKU AP52607A

Adipotide is an experimental research peptide designed to study a different approach to fat and metabolic research. Rather than acting primarily through appetite-regulating pathways, it was developed to recognize molecular targets associated with the blood vessels supplying white adipose tissue.

Preclinical research has investigated whether targeting this vascular network can alter the maintenance of white fat tissue. Animal studies have reported reductions in body weight and adipose tissue together with changes in metabolic measurements, making Adipotide an interesting model for studying adipose-tissue biology and vascular targeting.

Adipotide remains an investigational compound. Its effects have been studied primarily in laboratory and animal models, and results from these studies should not be interpreted as established effects in humans. This material is intended for laboratory research only, is not authorized by Health Canada for human therapeutic use, and is not intended for human or veterinary administration.


CA$69.99

In Stock

Choose a kit option to save more, or skip this and buy individually above.

Save 11%
2 Vials x 5mg
CA$125.00 CA$140.00
Save 14%
4 vials x 5mg
CA$240.00 CA$280.00
Save 20%
6 Vials x 5mg
CA$335.00 CA$420.00
Save 25%
10 Vials x 5mg
CA$525.00 CA$700.00
HPLC Purity Verified
Batch Documented
LC-MS Confirmation Available
2°C Storage

*LC-MS identity confirmation may be performed when analytical review indicates conflicting, atypical, or inconclusive results.

Adipotide — Research Overview

What Is Adipotide?

Adipotide is a synthetic, targeted peptide construct developed for research into white adipose tissue and the vascular system that supports it. It is sometimes described as an adipose-targeting peptide because its design combines a targeting sequence with a biologically active peptide sequence.

The targeting portion contains the peptide motif CKGGRAKDC, which was identified through experimental research examining molecules capable of preferentially interacting with blood vessels associated with white adipose tissue. Researchers subsequently identified prohibitin as an important binding target associated with this system.

This makes Adipotide fundamentally different from incretin-based research compounds. Its experimental mechanism does not primarily revolve around GLP-1, GIP, glucagon signalling, or appetite suppression. Instead, researchers have used it to investigate whether adipose tissue can be influenced by selectively targeting its supporting vascular environment.

How Adipotide Has Been Studied

Adipose tissue requires a continuous blood supply to provide oxygen and nutrients. Research into Adipotide explored the concept that selectively affecting blood vessels associated with white adipose tissue could change the ability of that tissue to remain established.

The CKGGRAKDC targeting sequence has been associated with prohibitin located on adipose-associated vascular cells. The peptide construct then carries a pro-apoptotic sequence intended to produce cellular effects after reaching the targeted tissue.

This targeted approach has been investigated as a way of studying the relationship between:

  • white adipose tissue and its vascular supply;
  • prohibitin and adipose-tissue biology;
  • vascular targeting and fat-mass regulation;
  • adipose tissue and insulin sensitivity;
  • targeted peptide delivery systems; and
  • metabolic changes following alterations in adipose tissue.

Later research has continued to examine prohibitin's role in adipose-tissue biology, including its involvement in fatty-acid transport and metabolic regulation.

What Has Preclinical Research Shown?

Initial animal research demonstrated that the CKGGRAKDC targeting motif could localize to the vasculature associated with white adipose tissue. When connected to a pro-apoptotic peptide sequence, researchers observed loss of white adipose tissue and metabolic changes in experimental models.

A later study investigated Adipotide in obese Old World monkeys. Researchers reported decreases in body weight, BMI, abdominal circumference and total body fat during the experimental treatment period, together with improvement in measurements of insulin resistance.

In one fixed-dose rhesus-monkey experiment, the investigators reported an average reduction of approximately 10.6% in body weight over the 28-day experimental period. Importantly, the study also identified predictable changes in renal proximal-tubule function, demonstrating that the experimental effects were not limited solely to adipose tissue.

These findings are significant from a research perspective because non-human primates are biologically closer to humans than traditional rodent models. They nevertheless remain preclinical findings and cannot establish effectiveness or safety in humans.

Human Research Remains Limited

Adipotide has not developed the large body of human clinical evidence available for established metabolic medicines.

A first-in-human Phase I study involving a prohibitin-targeting peptide was registered to investigate this research approach in people with metastatic prostate cancer and obesity. The registered study was subsequently terminated, and ClinicalTrials.gov lists no study results.

Consequently, claims about human weight reduction, metabolic improvement, safety, optimal exposure, or long-term outcomes cannot presently be established from the available clinical evidence.

Why Adipotide Remains Scientifically Interesting

Adipotide represents an unusual experimental approach because it investigates adipose tissue itself and the vascular network supporting that tissue, rather than focusing primarily on appetite or gastrointestinal hormone signalling.

Research into this pathway also continues beyond the original Adipotide molecule. More recent preclinical work has investigated newer prohibitin-targeting peptide designs as potential approaches for modifying adipose biology and body-weight regulation.

For researchers, Adipotide therefore remains relevant to investigations involving adipose vasculature, prohibitin targeting, targeted peptide delivery, metabolic biology, obesity models and experimental approaches to regulating white adipose tissue.


Adipotide Product Specifications

Product identification

Adipotide is a synthetic targeted peptide construct developed for experimental research involving adipose-tissue vasculature. Its structure combines the CKGGRAKDC targeting sequence with a pro-apoptotic D-amino-acid peptide sequence. In preclinical research, the targeting portion has been investigated for its interaction with prohibitin associated with white-adipose-tissue vasculature.

  • Product name: Adipotide
  • Full descriptive name: CKGGRAKDC-GG-D(KLAKLAK)₂
  • Common names: Adipotide
  • Research designation: Adipose-targeting pro-apoptotic peptide
  • Sequence: CKGGRAKDCGGKLAKLAKKLAKLAK
  • Peptide length: 25 amino-acid residues
  • Chemical class: Synthetic targeted peptide / peptidomimetic
  • Targeting sequence: CKGGRAKDC
  • Experimental molecular target: Prohibitin associated with adipose vasculature
  • CAS number: 859216-15-2
  • PubChem CID: 163360068
  • Molecular formula: C₁₁₁H₂₀₆N₃₆O₂₈S₂
  • Molecular weight: Approximately 2557.2 g/mol
  • Appearance: White to off-white dried peptide material; actual appearance may vary by formulation and batch
  • Solubility: Dependent on concentration, pH, formulation and supplied chemical form
  • Available nominal strength: 5 mg per vial
  • Format: Lyophilized research material in a sealed vial
  • Intended classification: Laboratory research material

The molecular formula, molecular weight and sequence above describe the Adipotide structure catalogued by PubChem. The C-terminal portion contains D-amino-acid residues, which are an important feature of the defined molecule and should be considered when establishing analytical identity.

Molecular structure and composition

Adipotide consists of two functional peptide regions connected through a glycine-glycine spacer. The N-terminal CKGGRAKDC sequence functions as the targeting component and has been investigated for recognition of prohibitin associated with the vasculature of white adipose tissue. The second portion contains the pro-apoptotic sequence D(KLAKLAK)₂, constructed using D-amino-acid residues.

The complete reported sequence is CKGGRAKDCGGKLAKLAKKLAKLAK. PubChem identifies the first eleven residues as L-amino acids or glycine, followed by a fourteen-residue D-amino-acid segment.

  • Targeting region: CKGGRAKDC
  • Linker region: GG
  • Effector region: D(KLAKLAK)₂
  • Total peptide length: 25 residues
  • Molecular formula: C₁₁₁H₂₀₆N₃₆O₂₈S₂
  • Average molecular weight: Approximately 2557.2 g/mol
  • Exact mass: Approximately 2556.53 Da
  • Structural feature: Contains both L- and D-amino-acid residues
  • Disulfide status: The two cysteine residues are represented as free thiol-containing residues in the PubChem canonical structure

These molecular values describe the reference structure and should not by themselves be interpreted as confirmation of the composition of an individual vial. Identity, peptide quantity, counterions, water content and other material characteristics require appropriate batch-specific analysis.

Physical specifications

  • Physical state: Solid research material
  • Typical presentation: Dried or lyophilized material in a sealed vial
  • Typical colour: White to off-white; actual appearance may vary by manufacturing process and formulation
  • Nominal fill: As stated on the product label and applicable batch record
  • Current nominal strength: 5 mg
  • Current batch: AP52607A
  • Purity statement: Report only the result supported by the applicable batch analysis
  • Peptide content: Batch-specific; requires quantitative analysis for confirmation
  • Counterion content: Not established unless specifically measured
  • Water content: Not established unless specifically measured
  • Solvent or diluent included: None unless expressly listed
  • Sterility status: Not tested unless supported by validated batch-specific testing
  • Endotoxin status: Not tested unless supported by validated batch-specific testing
  • Injectable preparation: No
  • Pharmaceutical dosage form: No
  • Finished therapeutic product: No

The term “lyophilized” should be used only where freeze-drying is confirmed by the manufacturer or applicable batch documentation. Powder appearance or cake size cannot establish peptide identity, purity, quantity, sterility or endotoxin status.

Analytical specifications

Chromatographic purity: High-performance liquid chromatography or LC-MS chromatography may be used to separate the principal peptide-related component from detectable impurities under a defined analytical method. The resulting purity percentage is generally a relative chromatographic measurement and should not automatically be interpreted as total active-peptide content by weight.

Appropriate chromatographic documentation should identify the product, batch number, sample-preparation procedure, analytical method, column or separation system, mobile-phase conditions, detection method, principal peak, calculated purity, analysis date and laboratory authorization.

Identity assessment: Mass spectrometry can support identification by comparing experimentally measured molecular ions with the expected molecular mass of Adipotide. The expected average molecular weight of the reference structure is approximately 2557.2 g/mol.

Sequence and stereochemistry: Standard molecular-mass analysis can support molecular identity but does not necessarily establish every stereochemical feature of a complex peptide. Because the Adipotide reference structure contains a substantial D-amino-acid segment, analytical conclusions should be limited to what the individual testing method can establish.

Depending on the research application, a broader analytical package may include:

  • HPLC or UPLC for peptide-related purity
  • LC-MS or high-resolution MS for molecular identity
  • Quantitative peptide assay against an appropriate reference standard
  • Peptide-mapping or sequence-confirmation procedures
  • Water-content testing
  • Residual-solvent analysis
  • Counterion assessment
  • Gravimetric or quantitative fill verification
  • Additional structural analysis when stereochemical confirmation is required

Only analyses completed for the applicable batch should be presented as verified product attributes.

Batch-testing information

Batch-specific analytical information should be reported only from documentation corresponding directly to the material being offered.

  • Current product: Adipotide
  • Nominal strength: 5 mg
  • Batch number: AP52607A
  • Chromatographic purity: Report according to the applicable Certificate of Analysis
  • Molecular identity: Report according to the applicable Certificate of Analysis
  • Measured peptide content: Report only where quantitative testing has been performed
  • Water content: Not established unless reported
  • Residual solvents: Not established unless reported
  • Counterion content: Not established unless reported
  • Sterility: Not tested unless supported by batch-specific testing
  • Endotoxin: Not tested unless supported by batch-specific testing
  • Microbial limits: Not tested unless supported by batch-specific testing

Chromatographic purity, molecular identity, measured peptide content and total lyophilized material are separate analytical measurements. A chromatographic purity percentage should not be multiplied by the total weight of dried material and presented as confirmed Adipotide quantity unless the analytical method and quantitative assay support that calculation.

Storage specifications

Keep the unopened material in its original sealed container, protected from direct light and moisture. Use the storage temperature supported by supplier documentation or stability information for the applicable batch rather than assuming a validated storage condition where one has not been established.

  • Keep the container sealed during storage
  • Protect the material from direct light and moisture
  • Avoid repeated temperature changes
  • Minimize unnecessary exposure to ambient humidity
  • Prevent contamination during laboratory handling
  • Do not assume stability after opening, transfer or preparation

If cold storage is specified in qualified product documentation, allow the sealed container to approach the intended laboratory handling temperature before opening when condensation is a concern. Any expiry or retest date should be supported by manufacturer documentation or appropriate stability data.

Intended use and restrictions

This product is supplied exclusively as a laboratory research material. It is not manufactured or released as a sterile drug product, injectable preparation, food, dietary supplement, natural health product, veterinary product or finished therapeutic product.

It is not intended for:

  • Human consumption or administration
  • Veterinary administration
  • Injection or compounding
  • Diagnosis, treatment, mitigation or prevention of disease
  • Food or beverage use
  • Household use

No human dosage, administration route, reconstitution schedule or treatment protocol is provided. Published laboratory and animal findings involving Adipotide do not establish the safety or effectiveness of this independently supplied research material in humans.

Documentation notice

These specifications describe the general identity, physical characteristics, analytical boundaries and intended research classification of Adipotide. Final release information must be based on the Certificate of Analysis and manufacturing documentation for the specific batch.

Where general product information and batch-specific documentation differ, the discrepancy should be resolved before publication or research use. Customers should review the applicable analytical records before beginning laboratory work. A Certificate of Analysis reports only the sample and tests described; it is not evidence of regulatory authorization, clinical safety or therapeutic effectiveness.

Certificates & Lab Reports

TESTING METHODOLOGY

Each batch undergoes analytical review using validated laboratory procedures. HPLC testing is utilized to assess purity and compare the sample profile against established reference standards. Where additional verification is warranted, LC-MS analysis may be performed to support compound identity confirmation.

OUR ANALYTICAL VERIFICATION PROGRAM

  • Primary Testing: HPLC purity analysis and reference comparison
  • Identity Confirmation: LC-MS performed when indicated*
  • Quality Standards: Batch traceability, analytical documentation, third-party testing and storage procedures

*See LC-MS Confirmation Information for full details.

Every batch supplied by Vanguard Compound Research is assigned a unique batch number and maintained under documented quality-control procedures with supporting analytical documentation available upon request.

SHIPPING & FULFILLMENT

FULFILLMENT INFORMATION
Ships from Canada

All orders ship from within Canada.

Batch Documentation Available

Batch records and analytical documentation may be provided for qualifying products.

Secure Packaging

Products are packaged securely to ensure safe delivery.

Tracking Provided

Tracking information is provided for every shipment.

Temperature-Conscious Handling

Frozen or ambient-safe packaging used as appropriate.

All Vanguard Compound Research orders are shipped directly from within Canada, ensuring efficient delivery, reliable service, and consistent quality-control from fulfillment to arrival.

Canadian Researchers Benefit From:

  • Domestic shipping with no customs delays
  • Batch-specific third-party laboratory testing
  • Full lot number traceability on every product
  • Access to batch-specific Certificates of Analysis (COAs)
  • Dedicated customer support

Canada-Wide Fulfillment:

  • Orders processed Monday through Friday
  • Shipments dispatched throughout Canada
  • Discreet and secure packaging
  • Tracking provided with every shipment

Batch Documentation & Testing

Products are maintained under documented quality-control procedures to help ensure quality, consistency, and transparency.

  • HPLC purity analysis
  • Reference-standard comparison
  • Additional verification procedures (e.g. LC-MS confirmation) may be performed where warranted
  • Lot number traceability

Each product is assigned a unique lot number, allowing researchers to match their item directly to its corresponding Certificate of Analysis (COA).

Analytical Documentation

Supporting analytical documentation may be available for qualifying products, including batch-specific quality records and testing information.

Documentation may include:
  • Batch Number
  • Analytical Results
  • Traceability Records
  • Storage Information

RELATED PRODUCTS